<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11862681</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.816</article-id><article-id pub-id-type="other">EPV0004</article-id><article-id pub-id-type="pii">S0924933824008162</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Viewing</subject></subj-group></article-categories><title-group><article-title>Cannabinoid syndrome in cannabis dependence: a case report</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Pichilingue Reto</surname><given-names>C.</given-names></name><xref rid="aff1952" ref-type="aff"/><xref rid="cor0677" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Jose Rojo</surname><given-names>A. M.</given-names></name><xref rid="aff1952" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Carrillo Reche</surname><given-names>M. B.</given-names></name><xref rid="aff1952" ref-type="aff"/></contrib></contrib-group><aff id="aff1952">Psychiatry, <institution>Benito Menni CASM</institution>, <city>Barcelona</city>, <country>Spain</country></aff><author-notes><corresp id="cor0677"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="791">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S398</fpage><lpage>S398</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824008162a.pdf"/><abstract><sec id="sec4069"><title>Introduction</title><p>A 36-year-old man with a history of cannabis use disorder since age 16, consuming 8-10 units/day, experienced irritability and tremors upon reducing consumption. His psychiatric issues emerged in 2020, marked by anxiety, abdominal pain, and severe vomiting, leading to a dyspepsia diagnosis. Subsequently, he received psychiatric care at CAS Hospitalet, diagnosed with severe cannabis use disorder. No prior inpatient admissions occurred.</p></sec><sec id="sec4070"><title>Objectives</title><p>
Our project aims to show a case report and summarize the available evidence on cannabinoid hyperemesis syndrome (CHS).</p></sec><sec id="sec4071"><title>Methods</title><p>In May 2023, he voluntarily sought admission to Barcelona&#x02019;s &#x0201c;Hospital Sant Pau,&#x0201d; aiming for cannabis detox and treatment of cannabinoid hyperemesis. He&#x02019;d endured years of intense abdominal pain, nausea, and vomiting, worsening over the last two years, with uncontrollable vomiting hindering daily life. Admission saw reduced cannabis use to 3-4 units/day. Inpatient care revealed anticipatory anxiety, rumination, and somatic anxiety, accompanied by distal tremors and internal restlessness due to abdominal discomfort, partially alleviated by 5-10 mg of diazepam.</p></sec><sec id="sec4072"><title>Results</title><p>Treatment included domperidone 10mg/8h, haloperidol drops (5-10 drops/8h), capsaicin ointment, hot showers, and cryotherapy, resulting in gradual relief from abdominal pain. Moderate cravings for tobacco and cannabis led to acetylcysteine 600mg/12h and gabapentin up to 1200mg/8h. Gastric discomfort with SSRIs led to vortioxetine 10 mg/day, well-tolerated with a positive response. Consultation with the GI department confirmed the treatment&#x02019;s efficacy, emphasizing cannabis abstinence. Upon discharge, cannabinoid hyperemesis symptoms markedly improved, and the patient was referred to &#x0201c;Hospital de Dia.&#x0201d;</p></sec><sec id="sec4073"><title>Conclusions</title><p>
CHS is a cyclic vomiting syndrome, preceded by daily to weekly chronic longstanding use of cannabis that can be difficult to diagnose and treat(1,3,4). It is unique in presentation, because of the cannabis&#x02019;s biphasic effect as anti-emetic at low doses and pro-emetic at higher doses, and the association with pathological hot water bathing (2). The major characteristics are as follows: history of regular cannabis for any duration of time (100%), cyclic nausea and vomiting (100%), resolution of symptoms after stopping cannabis (96.8%), compulsive hot baths with symptom relief (92.3%), male predominance (72.9%), abdominal pain (85.1%), and at least weekly cannabis use (97.4%)(1). Treatments such as topical capsaicin, haloperidol, benzodiazepines, and propranolol have shown symptom relief (3) whereas opioids should be avoided (4). Cannabis cessation appears to be the best treatment (1,3).</p></sec><sec id="sec4074"><title>References</title><p>
<list list-type="order"><list-item><p>Sorensen et al.&#x000a0;<italic toggle="yes">Journal of Medical Toxicology</italic>&#x000a0;13 (2017):71-87.</p></list-item><list-item><p>Perisetti et al. <italic toggle="yes">Annals of gastroenterology</italic>&#x000a0;33.6 (2020):571.</p></list-item><list-item><p>Senderovich et al.&#x000a0;<italic toggle="yes">Medical Principles and Practice</italic>&#x000a0;31.1 (2022):29-38.</p></list-item><list-item><p>Leu, et al. <italic toggle="yes">Journal of Emergency Nursing</italic>&#x000a0;47.3 (2021): 483-486</p></list-item></list></p></sec><sec id="sec4075"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>